Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol

Annals of Oncology : Official Journal of the European Society for Medical Oncology
P PeregoF Zunino

Abstract

Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of ovarian carcinoma to cisplatin. However, cisplatin resistance is likely to be multifactorial. An understanding of the molecular alterations associated with the development of resistance may be of considerable relevance in an attempt to optimize the therapeutic approach. Two cisplatin-resistant sublines (IGROV-1/Pt0.5 and IGROV-1/Pt1), both characterized by mutant p53 (Cancer Res 1996; 56: 556-62), but with different degree of resistance were studied in terms of pattern of cross-resistance, susceptibility to drug-induced apoptosis, expression of gluthathione-dependent system, cellular pharmacokinetics, drug-induced DNA damage. The resistance index (ratio between the IC50 of resistant and sensitive cells) after a 96-hour drug exposure was 10 for IGROV-1/Pt0.5 and 14 for IGROV-1/Pt1 cells. Resistant cells were cross-resistant to DNA-damaging agents and, interestingly, they had a collateral sensitivity to Taxol. The cellular response to Taxol paralleled the drug ability to induce apoptosis. The intracellular glutathione level was significantly increased in IGROV-1/Pt cells compared to the sensitive counterpart. In contrast, glutathion...Continue Reading

Citations

Jul 18, 2016·Journal of Cancer Research and Clinical Oncology·Mirjam GerwingFriedemann Honecker
Jul 18, 2000·Anti-cancer Drugs·W DempkeH J Schmoll
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·G CassinelliF Zunino
Feb 9, 2000·Japanese Journal of Cancer Research : Gann·Y MinagawaN Terakawa
Apr 13, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R UsluE Goker
Nov 25, 2014·Organic & Biomolecular Chemistry·Maria VetroDiego Colombo
Sep 2, 1999·International Journal of Cancer. Journal International Du Cancer·M V Blagosklonny, T Fojo
Jul 18, 2000·International Journal of Cancer. Journal International Du Cancer·P PeregoF Zunino
Jan 31, 2015·Journal of Cancer Research and Clinical Oncology·Oluwafunmilayo F LamidiIan N Fleming
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LavarinoF Zunino
Jan 5, 2002·Journal of the National Cancer Institute. Monographs·M J PiccartM Buyse
Jun 22, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claudio PisanoFranco Zunino
Jan 12, 2021·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Luciana MoscaGianni Colotti
Aug 23, 2001·Mutation Research·M L Dronkert, R Kanaar
May 12, 2021·ACS Nano·Xiaotong ChengFu-Gen Wu
Nov 19, 2009·Molecular Pharmaceutics·Laura GattiFranco Zunino
Jun 24, 2021·Proceedings of the National Academy of Sciences of the United States of America·Shengqing GuBenjamin G Neel
Jul 25, 2018·Bioorganic & Medicinal Chemistry·Zuleyha OzenM Kyle Hadden
Nov 22, 2013·Molecular Pharmaceutics·Laura GattiPaola Perego
Mar 6, 2007·Critical Reviews in Oncology/hematology·David J Stewart
Aug 15, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·May T MaungTeresita Padilla-Benavides
Aug 18, 2021·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Andreia ValentePetra Heffeter
Feb 19, 2008·Journal of Inorganic Biochemistry·Giovanni Luca BerettaPaola Perego
Sep 19, 2009·Trends in Pharmacological Sciences·Matthew D HallMichael M Gottesman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis